Challenges in developing a pediatric RSV vaccine

 Abstract

RSV bronchiolitis is the leading cause of infant hospitalization in industrialized countries.  There is an unmet need to prevent RSV lower respiratory tract infection in young infants.  Although many vaccinology approaches, including live attenuated, viral and bacterial vectored and adjuvanted subunit vaccines have been evaluated in rodent and primate models there is currently no approved RSV vaccine.  A vaccine candidate for RSV-naive infants must provide immunogenicity in the presence of maternally acquired antibodies, avoid enhanced disease, and have minimal reactogenicity. Because live RSV infection does not potentiate for enhanced disease and elicits systemic and mucosal immune responses, live RSV vaccine candidates are currently preferred.  Two live attenuated RSV vaccine candidates,  rA2cpts248/404/1030/ΔSH, a temperature sensitive RSV with a deletion of the SH gene, and rb/h PIV3/RSV F2 which has RSV F vectored into a bovine/human chimeric parainfluenza type 3 genome, have recently advanced into clinical studies.

Full Text Options
Article
Metrics
 Share
 Info
Pages
582 - 591
Type
Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Challenges in developing a pediatric RSV vaccine